[HTML][HTML] Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective …

G Margiotta-Casaluci, S Bigliardi, F Cocito… - Frontiers in …, 2023 - frontiersin.org
In the setting of follicular lymphoma (FL), frontline therapy with rituximab, cyclophosphamide,
doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of …

Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study …

G Margiotta-Casaluci, S Bigliardi, F Cocito… - Frontiers in …, 2023 - europepmc.org
In the setting of follicular lymphoma (FL), frontline therapy with rituximab, cyclophosphamide,
doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of …

[HTML][HTML] Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective …

G Margiotta-Casaluci, S Bigliardi, F Cocito… - Frontiers in …, 2023 - frontiersin.org
In the setting of follicular lymphoma (FL), frontline therapy with rituximab, cyclophosphamide,
doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of …

[HTML][HTML] Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective …

G Margiotta-Casaluci, S Bigliardi, F Cocito… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
In the setting of follicular lymphoma (FL), frontline therapy with rituximab, cyclophosphamide,
doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of …

Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study …

G Margiotta-Casaluci, S Bigliardi… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
In the setting of follicular lymphoma (FL), frontline therapy with rituximab, cyclophosphamide,
doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of …